Chronic Lyme borreliosis at the root of multiple sclerosis--is a cure with antibiotics attainable?

Heeft u de diagnose MS? Er zijn veel MS patienten die zich lieten testen door een ILADS arts en Lyme bleken te hebben
As minocycline, tinidazole and hydroxychloroquine are reportedly capable of destroying both the spirochaetal and cystic L-form of B. burgdorferi found in MS brains.
Dr. Klinghardt stated in one of our interviews that he's never had a single patient with Alzheimer's, ALS, Parkinson's disease or multiple sclerosis who tested negative for Borrelia.
Vincent Marshall is een onderzoeker die veronderstelde dat MS een chronische ziekte van het centrale zenuwstelsel is welke veroorzaakt wordt door de spirocheet Borrelia. Zijn artikel uit 1988 gepubliceerd in het blad Hypothesis verwees naar een eerder artikel uit 1954, waarin gekeken werd naar de bacteriële etiologie voor MS, gebruikmakend van zilverkleuringen in zenuw leasies, en dierlijke isolatie van de laesies veroorzakende bacterie. Marshall geeft in zijn artikel aan dat de demyelinisatie van het zenuwstelsel behandeld kan worden met hoge dosis antibiotica welke de bloed-hersenbariëre kunnen passeren en het centrale zenuwustelsel kunnen bereiken alsook de mogelijkheid biedt tot het maken van een vaccin.
Microbioloog Dr Hoekstra:
Dr. Hoekstra's mentor was Lida Holmes Mattman.
Lida Mattman heeft de Borrelia bacterie 50 jaar bestudeerd en is genomineerd voor de Nobel prijs. Zij heeft veel ontdekt en bewezen wbt de Borrelia bacterie.

A different bacteria, operating on similar principles, seems to be the organic cause of multiple sclerosis, says Dr. Hoekstra. It's tentative name--not yet widely accepted by other microbiologists--is Borrelia mylophora, so named because its characteristics seem to resemble those of Borrelia burgdorferi, the bacteria believed responsible for Lyme disease.
In multiple sclerosis, the myelin sheath covering nerves gets eaten away by the immune system, explains Dr. Hoekstra. "That is exactly like the hunters' torches setting fire to the forest. Most of the destruction of the myelin sheath takes place from actions of the white blood cells and their antibodies. But their primary target is not the myelin sheath at all. It's the Borrelia mylophora bacteria, running around in the nervous system.
B. mylophora has an extremely high affinity for the myelin sheath. It loves it."
Unfortunately, the myelin sheath sustains a lot of collateral damage as the immune cells attempt to find and destroy the microbe, Dr. Hoekstra says.
The work on identifying a possible microbial agent in multiple sclerosis has been under way for many years, since 1913. One of the difficulties is the microbiologist must be very patient, able to culture a blood specimen and keep it uncontaminated for as long as nine months before a positive bacterial identification can be made, explains Dr. Hoekstra.
Both P. acnes and B. mylophora are examples of stealth pathogens, of organisms with deficient cell walls, capable of acting secretly in the body, creating disease, and hardly leaving a trace.
Pushing Away Their Wheelchairs
Once you understand the nature of the organism causing an autoimmune disease, it's much easier to develop an effective strategy against it, says Dr. Hoekstra. "We have a number of multiple sclerosis patients who have pushed away their wheelchairs or thrown away their canes and are walking now. And their vision has been restored," he adds.
Physicians use different strategies in dealing with the underlying bacteria. Dr. Hoekstra cites the example of Phoebe, a 36-year-old woman with MS. After B. mylophora was cultured from her blood, Phoebe's doctor prescribed a heavy dose (about 100 mg daily) of a standard antibiotic called doxycycline. After four weeks, she was able to lift both hands in the air, comb her hair without losing her balance, see clearly again without dizziness, and move about without her cane; after six months
(four of which involved continuous dosing), Phoebe was free of all symptoms, says Dr. Hoekstra.
The successful use of this antibiotic against B. mylophora was first verified by a physician in South Dakota who reasoned that the symptoms of MS (which he had) were suggestively similar to those of Lyme disease, which responds fairly well to doxycycline. After dosing himself for three months with the antibiotic, he was symptom free.

MS en Lyme
Het bleek dat er een significant aantal overlappende gevallen was van schizofrenie, MS, en de verdeling van Ixodes ricinus teken die de ziekte van Lyme in Europa verspreiden. Fritzsche observeerde dat gematigde temperatuur klimaten een hoger aantal infecties had van teken besmet met de Borrelia garinii, en dat dit infectie aantal overeen kwam met de verdeling van MS gevallen.
Bovendien merkte Fritzsche op dat nieuwe excessen van MS en die van schizofrenie negen maanden uit elkaar lagen. Dit suggereerde dat ze verband hielden met de activiteit van de Ixodes ricinus teek in Europa op het moment van zijn conceptie en geboorte. Ook in de VS werden deze negen maanden clusters van MS en schizofrenie gevonden wat de activiteit van de Ixodes pacificus en de Ixodus scapularis geboortecyclus weerspiegelden. Beide zijn ziekte van Lyme veroorzakende teken. Fritzsche spreekt hierin ook zijn bezorgdheid uit over de mogelijke overdracht van de ziekte van Lyme van moeder op kind tijdens de zwangerschap, alhoewel officiële richtlijnen nog steeds volhouden dat de ziekte van Lyme niet besmettelijk is.
Alan MacDonald zegt: Alles wat Syfiles kan, kan de Borrelia bacterie ook!!

Apart from its devastating impact on individuals and their families, multiple sclerosis (MS) creates a huge economic burden for society by mainly afflicting young adults in their most productive years.
Although effective strategies for symptom management and disease modifying therapies have evolved, there exists no curative treatment yet.
Worldwide, MS prevalence parallels the distribution of the Lyme disease pathogen Borrelia (B.) burgdorferi, and in America and Europe, the birth excesses of those individuals who later in life develop MS exactly mirror the seasonal distributions of Borrelia transmitting Ixodes ticks.
In addition to known acute infections, no other disease exhibits equally marked epidemiological clusters by season and locality, nurturing the hope that prevention might ultimately be attainable.
As minocycline, tinidazole and hydroxychloroquine are reportedly capable of destroying both the spirochaetal and cystic L-form of B. burgdorferi found in MS brains, there emerges also new hope for those already afflicted.
The immunomodulating anti-inflammatory potential of minocycline and hydroxychloroquine may furthermore reduce the Jarisch Herxheimer reaction triggered by decaying Borrelia at treatment initiation.
Even in those cases unrelated to B. burgdorferi, minocycline is known for its beneficial effect on several factors considered to be detrimental in MS. Patients receiving a combination of these pharmaceuticals are thus expected to be cured or to have a longer period of remission compared to untreated controls.
Although the goal of this rational, cost-effective and potentially curative treatment seems simple enough, the importance of a scientifically sound approach cannot be overemphasised.
A randomised, prospective, double blinded trial is necessary in patients from B. burgdorferi endemic areas with established MS and/or Borrelia L-forms in their cerebrospinal fluid, and to yield reasonable significance within due time, the groups must be large enough and preferably taken together in a multi-centre study.